ProHance 279.3 mg/mL (Gadoteridol INJECTION, SOLUTION) 279.3 mg/mL

ProHance 279.3 mg/mL is a gadoteridol injection used for contrast enhancement in MRI scans. This solution aids in visualizing internal structures for better diagnostic accuracy.

Strength

279.3 mg/mL

Pack Size

5 VIAL, SINGLE-DOSE in 1 BOX (0270-1111-01) / 10 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Bracco Diagnostics Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ProHance 279.3 mg/mL is primarily used as a contrast agent in magnetic resonance imaging (MRI). It helps to enhance the clarity of images, making it easier for healthcare professionals to identify and assess abnormalities. This gadoteridol injection is often utilized in diagnostic procedures to improve the visibility of tissues and organs.

Side Effects

When administered intravenously, ProHance 279.3 mg/mL may cause temporary discomfort at the injection site. Some individuals might experience a warm sensation or mild nausea. These effects are generally short-lived and subside quickly.

Precautions & Warnings

ProHance 279.3 mg/mL should be used with caution in individuals with a history of allergic reactions to gadolinium-based contrast agents. It is important to inform healthcare providers about any existing medical conditions or allergies before administration. Proper handling and storage are essential to maintain the integrity of the solution.

Avoid Interactions

ProHance 279.3 mg/mL may interact with certain medications or substances. It is advisable to discuss all current medications with a healthcare provider before using this contrast agent. Specific interactions with alcohol or other substances should be reviewed on a case-by-case basis.

Frequently Asked Questions

ProHance 279.3 mg/mL is used as a contrast agent in MRI scans to enhance the visibility of internal structures.

ProHance 279.3 mg/mL is administered intravenously by a healthcare professional during an MRI procedure.

Common effects may include temporary discomfort at the injection site and a warm sensation or mild nausea.

Individuals with a history of allergic reactions to gadolinium-based contrast agents should use ProHance 279.3 mg/mL with caution.

ProHance 279.3 mg/mL may interact with certain medications, so it is important to discuss all current medications with a healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.